These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11610 related articles for article (PubMed ID: 10661764)

  • 1. Regression of melanoma, but not keratoacanthoma, is associated with increased HLA-B22 and decreased HLA-B27 and HLA-DR1.
    Lowes MA; Dunckley H; Watson N; Crotty K; Cooke B; Barnetson RS; Halliday GM
    Melanoma Res; 1999 Dec; 9(6):539-44. PubMed ID: 10661764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells.
    Halliday GM; Patel A; Hunt MJ; Tefany FJ; Barnetson RS
    World J Surg; 1995; 19(3):352-8. PubMed ID: 7638987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of HLA-B and HLA-DR genes on susceptibility to and severity of spondyloarthropathies in Mexican patients.
    Vargas-Alarcón G; Londoño JD; Hernández-Pacheco G; Pacheco-Tena C; Castillo E; Cardiel MH; Granados J; Burgos-Vargas R
    Ann Rheum Dis; 2002 Aug; 61(8):714-7. PubMed ID: 12117677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Kageshita T; Ishihara T; Campoli M; Ferrone S
    Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30+ cells in regressing keratoacanthoma and in non-keratoacanthomatous squamous cell carcinoma.
    Fernandez-Flores A
    Bratisl Lek Listy; 2008; 109(11):508-12. PubMed ID: 19205562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to human keratoacanthoma.
    Flannery GR; Muller HK
    Br J Dermatol; 1979 Dec; 101(6):625-32. PubMed ID: 394758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA and skin cancer.
    Bonamigo RR; Carvalho AV; Sebastiani VR; Silva CM; Pinto AC
    An Bras Dermatol; 2012; 87(1):9-16; quiz 17-8. PubMed ID: 22481646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogene involvement in tumor regression: H-ras activation in the rabbit keratoacanthoma model.
    Corominas M; Leon J; Kamino H; Cruz-Alvarez M; Novick SC; Pellicer A
    Oncogene; 1991 Apr; 6(4):645-51. PubMed ID: 1840681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA antigen frequencies in renal transplant recipients and non-immunosuppressed patients with non-melanoma skin cancer.
    Glover MT; Bodmer J; Bodmer W; Kennedy LJ; Brown J; Navarrete C; Kwan JT; Leigh IM
    Eur J Cancer; 1993; 29A(4):520-4. PubMed ID: 8435203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positivity for HLA DR1 is associated with basal cell carcinoma in renal transplant patients in southern Brazil.
    de Carvalho AV; Bonamigo RR; da Silva CM; Pinto AC
    Int J Dermatol; 2012 Dec; 51(12):1448-53. PubMed ID: 23171011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H, peanut lectin receptor, and carcinoembryonic antigen distribution in keratoacanthomas, squamous dysplasias, and carcinomas of skin.
    Ariano MC; Wiley EL; Ariano L; Coon JS; Tetzlaff L
    J Dermatol Surg Oncol; 1985 Nov; 11(11):1076-83. PubMed ID: 3902925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible key role of granzyme B in keratoacanthoma regression.
    Batinac T; Zamolo G; Coklo M; Hadzisejdic I
    Med Hypotheses; 2006; 66(6):1129-32. PubMed ID: 16497444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of constitutively active V599EBRaf.
    Andersen MH; Fensterle J; Ugurel S; Reker S; Houben R; Guldberg P; Berger TG; Schadendorf D; Trefzer U; Bröcker EB; Straten Pt; Rapp UR; Becker JC
    Cancer Res; 2004 Aug; 64(15):5456-60. PubMed ID: 15289355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric HLA-B27 screening: cross-reactivity patterns of commercially available anti-HLA-B27 monoclonal antibodies with other HLA-B antigens.
    Levering WH; Wind H; Sintnicolaas K; Hooijkaas H; Gratama JW
    Cytometry B Clin Cytom; 2003 Jul; 54(1):28-38. PubMed ID: 12827665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HLA-antigens and some pathogenetic aspects of reactive arthritis].
    Sidel'nikova SM; Kut'ina RM; Zotikov EA
    Ter Arkh; 1998; 70(5):20-4. PubMed ID: 9644736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smooth muscle-associated antigen in experimental cutaneous squamous cell carcinoma, keratoacanthoma, and papilloma.
    Toh BH; Muller HK
    Cancer Res; 1975 Dec; 35(12):3741-5. PubMed ID: 811354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma.
    Waring AJ; Takata M; Rehman I; Rees JL
    Br J Cancer; 1996 Mar; 73(5):649-53. PubMed ID: 8605102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta 2 microglobulin expression in keratoacanthomas and squamous cell carcinoma.
    Graham RM; MacFarlane AW; Curley RK; Nash JR
    Br J Dermatol; 1987 Oct; 117(4):441-9. PubMed ID: 3314969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis.
    Pollack MS; Livingston PO
    Tissue Antigens; 1985 Oct; 26(4):262-5. PubMed ID: 3878014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Another contribution to the problem of keratoacanthomas].
    Maggiora A
    Dermatologica; 1968; 137(4):2639. PubMed ID: 5685903
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 581.